The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes

Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine

EJHaemLast synced 7/31/2026Status: syncedPMID: 42529759 pmidDOI: 10.1002/jha2.70366

ABSTRACT : To study the predictive and prognostic values of serum erythropoietin levels (sEPO) measured at diagnosis in lower‐risk myelodysplastic syndromes. : We analyzed clinical associations and prognosis with sEPO in 672/1610 patients with at least one year of follow‐up data in the prospective EUMDS study. : sEPO levels increase with WHO subtypes associated with erythroid hypoplasia and poorer risk IPSS‐R scores. sEPO is an independent predictor of transfusion free survival and levels < 200 IU/L predict response to ESA. sEPO is not an independent predictor of overall survival. : sEPO predicts transfusion free survival and response to ESA. : The EUMDS Registry (ClinicalTrials.gov: Identifier).

Educational only

This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.